Forward-looking statements
|
|
- Melissa Spencer
- 6 years ago
- Views:
Transcription
1 March 2017
2 Forward-looking statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of our most recent Annual Report on form 10-K or Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and made available on our website at When evaluating Agenus business and prospects, careful consideration should be given to these risks and uncertainties. These statements speak only as of the date of this presentation, and Agenus undertakes no obligation to update or revise these statements. This presentation and the information contained herein do not constitute an offer or solicitation of an offer for sale of any securities. 2
3 Broad I-O portfolio: enabling optimal combos 3
4 Agenus Five Year Growth Plan: balancing low & high risk initiatives Advance on most rapid path to BLA Develop, register, and launch anti-pd-1/ctla-4 mab combinations in validated indications Pursue novel breakthrough indications to expedite market entry Leverage novel targets for market expansion Pursue optimal I-O mab and vaccine combinations with anti-ctla-4 +/- anti-pd-1 Progress partnered programs (GITR, OX40, TIM-3, LAG-3) towards registration Advance Ab programs against innovative undisclosed targets to the clinic Engage in strategic partnerships 4
5 Current partnerships QS-21 Stimulon : adjuvant for Shingrix GSK filed for registration in U.S., Canada and Europe Royalties and milestones partly monetized 1 undisclosed target Lead selection completed Up to $100 million in milestones Pre-clinical: LAG-3, TIM-3, TIGIT, 2 undisclosed Royalty rates are generally 6-12%* Clinical: GITR, OX40 Royalty rate 15% Up to $510 million in milestones across all programs * *Incyte eligible for 15% royalty for TIGIT 5
6 Clinical Strategy
7 New clinical development paradigm compressed Risk AGEN1884 / AGEN Vaccine AGEN1884 / AGEN2034 Solid Tumors Efficacy unknown AGEN1884 / AGEN Novel CPM (A, B, C) AGEN1884 / AGEN2034 Solid Tumors Efficacy proven Conventional time to BLA AGEN1884 = anti-ctla-4 mab AGEN2034 = anti-pd-1 mab CPM = checkpoint modulator 10 years 7
8 anti-ctla-4 + anti-pd-1: first clinically validated I-O mab combo anti-ctla-4 (low dose) combined with anti-pd-1/pd-l1 is the only validated mab combination with improved efficacy and safety profile Near doubling of clinical response - from 25% to ~57% in NSCLC (1) Control of CTLA-4 + PD-1/PD-L1 targeted therapies could offer a pricing advantage Provides a foundation for mabs against novel checkpoints that are yet to show efficacy in the absence of CTLA-4 antagonism 1. Hellmann et al. Lancet Oncol 2017 *Anti-CTLA-4 antibody AGEN1884 is partnered with Recepta for certain South American territories 8
9 Targeting PD-1 has clinical benefit but combining with CTLA-4 antagonism works better anti-ctla-4 (low dose) combination with anti-pd-1/pd-l1 reduces development risk and expands markets anti-ctla-4 and anti-pd-1 mab combination is already approved in metastatic melanoma & almost doubles clinical benefit in 1L NSCLC (1) CTLA-4 + PD-1/PD-L1 antagonists +/- mabs targeting novel checkpoints have shown compelling data in preclinical models 1. Hellmann et al. Lancet Oncol 2017 *Anti-CTLA-4 antibody AGEN1884 is partnered with Recepta for certain South American territories 9
10 Metastatic virally induced malignancies*: appealing target for Agenus Clinical development: SOC marginally changed after the approval of Avastin in combination with chemo in 1L No effective treatment options in 2L; unmet medical need Clinical activity of other anti PD-X in virally induced and HPV driven malignancy (HNSCC HPV+) suggests that AGEN1884 administration could lead to an ORR 15% in all comers, > 20% in PD-L1+ Regulatory: US: Possibility of applying for Breakthrough Designation, assuming hypotheses are backed up by clinical data, Accelerated Approval possible EU: Possibility of applying for conditional marketing authorization Commercial: Potential niche opportunity with most of the patients from Japan and South Korea where premium prices for unmet medical needs are commonly given and where there is no off-label use reimbursed * Anticipated in cervical cancer 10
11 AGEN2034 (anti-pd-1) and AGEN1884 (anti-ctla-4): projected clinical inflection points Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 First patient for 2034 dose escalation Phase 1 n = 30 Dose is established 2L Virally-induced Cancer ** First patient for dose escalation Phase 1b n = 30 Virally-induced Cancer PD-1 vs PD-1 + CTLA-4 vs SOC * Top line data *** US filing US approval ** ** * Anticipated in cervical cancer ** Projections 11
12 Preclinical data
13 Sculpting the immune response to maximize clinical benefit Checkpoint mabs Anti-4-1BB Anti-OX40** Anti-GITR** Checkpoint mabs Anti-CTLA-4* Anti-PD-1* Anti-TIGIT Anti-TIM-3** Anti-LAG-3** Vaccine Platforms Prophage AutoSynVax (ASV ) PhosphoSynVax (PSV ) Neoantigen vaccines: ASV, PSV Adjuvant: QS-21 Stimulon Anti-CTLA-4* Anti-PD-1* * Partnered with Recepta for certain South American territories ** Partnered with Incyte 13
14 Integrated antibody discovery technologies, combined with immunology expertise 14
15 Agenus anti-ctla-4 mab improves primate vaccine response A n ti-h B s A g Ig G (U /m L ) S F U /1 x P B M C Antibody Vaccine Anti-CTLA-4 antibody AGEN Hepatitis B surface antigen (HBsAg) vaccine Humoral Response Cellular Response 2,0 0 0, ,5 0 0,0 0 0 A G E N (N = 6 ) C o n tr o l (N = 6 ) A G E N Is o ty p e c o n tro l 1,0 0 0, , A d m in is tra tio n s o f a n tib o d y o r v e h ic le (c o n tr o l) p lu s H B s A g v a c c in e Internal data (unpublished) D a y s A fte r In itia l D o s in g 15
16 P D -L 1 o r P D - L 2 b in d in g ( % ) IL - 2 (p g /m l) AGEN2034: Anti-PD-1 antagonist antibody PD-1 inhibits TCR-induced signaling to impair T cell effector function Response rates observed with an PD-1 antagonist in a range of solid and hematological tumor settings AGEN2034 binds to PD-1 with high affinity (nm) and potently inhibits PD-1 binding to PD-L1/ P D -L1 P D -L2 AG EN2034 iso type AG EN2034 iso type AGEN2034 enhances T cell responsiveness to suboptimal TCR activation AG EN2034 Is o ty p e A n tib o d y ( lo g g /m L ) A n tib o d y ( lo g g /m L ) Internal data (unpublished) 16
17 AGEN1884 combines in primary T cell assays with PD-1:PD-L1 blockade (as well as LAG-3) Isotype Pembrolizumab Internal data (unpublished) 17
18 Business
19 Projected milestones Accomplishments Clinical Deliverables Clinical Activity & Readouts Three CPM mabs in clinic CTLA-4 antagonist (AGEN1884)* GITR agonist (INCAGN1876)** OX40 agonist (INCAGN1949)** Clinical Development team with I-O development success on board QS-21 Stimulon containing Shingles vaccine filed for regulatory approval * Partnered with Recepta for certain South American rights ** Partnered with INCY Anticipated in cervical cancer Clinical trials Initiate Ph 1 for PD-1 antagonist (AGEN2034)* monotherapy Initiate virally-induced cancer trial (2L) Initiate Ph 1b with AGEN1884* with AGEN2034* Initiate Ph 1 with AutoSynVax Clinical results Optimal monotherapy dose for AGEN2034* Optimal combination dose of AGEN2034* + AGEN1884* Clinical responses Data from 30 patients Initial immune biomarker data from 6- patient Ph 1 ASV proof-of-mechanism trial Complete enrollment for 2 nd line virally-induced cancer cohort Top line data for the virallyinduced cancer cohort: Response rate Duration of response Safety and tolerability 19
20 Management Team Garo Armen, PhD, Chairman & CEO Elan Corporation, plc, Protagenic Therapeutics, Founder - Children of Armenia Fund (COAF) Robert Stein, MD, PhD, President, R&D Incyte Pharmaceuticals, Ligand Pharmaceuticals, Dupont/Merck, Roche, KineMed, Merck, Sharp & Dohme Jennifer Buell, PhD, VP R&D and External Affairs Harvard Clinical Research, Bristol-Myers Squibb Christian Cortis, PhD, VP Business Development Synta Pharmaceuticals, Advanced Technology Ventures, Columbia University Jean-Marie Cuillerot, MD, Chief Medical Officer EMD Serono, Bristol-Myers Squibb, University Louis Pasteur Alex Duncan, PhD, Chief Technology Officer Actigen, Affitech A/S, Astra Zeneca, Cambridge Antibody Technology Christine Klaskin, VP Finance Arthur Andersen, George Washington University Michelle Linn, VP Corporate Communications Linnden Communications, Ogilvy PR/Feinstein Kean, Chair of Women In Bio Boston Chapter Karen Valentine, JD, Chief Legal Officer & General Counsel Palmer and Dodge LLP 20
Jefferies 2018 Healthcare Conference June 7, 2018
Jefferies 2018 Healthcare Conference June 7, 2018 Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties,
More informationCell Therapy Business Entity. Jefferies IO Cell Therapy Summit
Cell Therapy Business Entity April 3rd 2018 Jefferies IO Cell Therapy Summit 1 Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements are subject
More informationGood morning and thank you for joining us for our quarterly update.
Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More informationProhost Letter #403 DECEMBER 14, Stories, Statements and Observations
Prohost Letter #403 DECEMBER 14, 2016 Stories, Statements and Observations On December 8, 2016 under News & Comments Prohost commented on President Elect Trump s statement that he is going to bring down
More informationPDS Biotechnology and Edge Therapeutics. Proposed Combination. November 26, A new generation of multifunctional
PDS Biotechnology and Edge Therapeutics Proposed Combination November 26, 2018 A new generation of multifunctional immunotherapies Forward-Looking Statements This presentation contains forward-looking
More informationFORWARD-LOOKING STATEMENTS
1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual
More informationStrategic Collaboration with Amgen to develop MP0310
Strategic Collaboration with Amgen to develop MP0310 Patrick Amstutz, CEO Webcast of Molecular Partners AG, Switzerland (SIX: MOLN) December 19, 2018 2018 Molecular Partners AG Slide 1 Molecular Partners:
More informationPolicy Issues in the Clinical Development and Use of Immunotherapy for Cancer
Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Cancer Immunotherapy Development 2014/2015 Approval of 2 anti-pd-1 antibodies for advanced melanoma and lung cancer http://www.fightcancerwithimmunotherapy.com
More informationCRITERIA FOR PROJECT SELECTION
CRITERIA FOR PROJECT SELECTION The CITN is a network of eperienced immunotherapy investigators with inherently diverse research interests. Thus, we have established guidelines to epedite project selection
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More informationCORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER March 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements
More informationInnovating Antibodies, Improving Lives. 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019
Innovating Antibodies, Improving Lives 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation contains forward looking statements. The words believe,
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationChanging the Practice of Cancer Treatment. 36 th Annual J.P. Morgan Healthcare Conference Hervé Hoppenot, Chief Executive Officer January 8, 2018
Changing the Practice of Cancer Treatment 36 th Annual J.P. Morgan Healthcare Conference Hervé Hoppenot, Chief Executive Officer January 8, 2018 Forward-looking Statements Except for the historical information
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationMPDL3280A (anti-pd-l1) in metastatic bladder cancer. Powles T et al. Nature 515(7528), (2014)
Combinations MPDL3280A (anti-pd-l1) in metastatic bladder cancer Powles T et al. Nature 515(7528), 558-562 (2014) Targeted Therapy Any therapy that targets cancer s specific phenotype or genotype Specific
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationVertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mrna Therapeutics for Cystic Fibrosis -Collaboration to explore use of mrna Therapeutics to treat the underlying cause of CF
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationARCUSBIOSCIENCES,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,DC20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d) ofthesecuritiesexchangeactof1934 DateofReport(Dateofearliesteventreported):May9,2018 ARCUSBIOSCIENCES,INC.
More informationNSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationCorporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationAgios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. The people pictured here are some of the many friends and family of Agios employees affected by cancer. All of us at Agios are passionate about transforming patients lives.
More informationGalena Biopharma, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationThe remarkable efficiency of chaperone-based synthetic cancer vaccines
The remarkable efficiency of chaperone-based synthetic cancer vaccines Daniel L. Levey, PhD Senior Director Vaccine Research June 21, 2018 Forward-looking statements This presentation contains forward-looking
More informationThe global leader in developing LAG-3 therapeutics
The global leader in developing LAG-3 therapeutics CEO Presentation Annual General Meeting November 2018 (ASX: IMM, NASDAQ: IMMP) Notice: Forward Looking Statements The purpose of the presentation is to
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationANNUAL REPORT. IderaPharma.com
ANNUAL REPORT 2016 IderaPharma.com FOCUSED FORWARD Fellow Idera Shareholders, Greetings, and I hope your 2017 is off to an outstanding start. I compose this letter with great optimism about Idera s direction
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Giovanni Caforio Chief Operating Officer January 13, 2015 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationTechnology Transforming Life
Technology Transforming Life Technology Transforming Life Licensing Executive Society USA Canada Emerging Enterprise Committee Commercialization: Building the Custom Fit for Success : Gary N. Keller, CLP
More informationCombination Therapies. Inhibitors
Combination Therapies with Immune The Value of Partnerships Checkpoint - Case Study - Inhibitors The Value of Partnerships - Case Study - New data is forecasting that the immune checkpoint inhibitor market
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFROM CODE TO CURE. Corporate Overview. January Anat Cohen-Dayag, PhD President & CEO.
FROM CODE TO CURE TM Corporate Overview January 2019 Anat Cohen-Dayag, PhD President & CEO 1 www.cgen.com SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning
More informationFROM CODE TO CURE. Corporate Overview. October Anat Cohen-Dayag, PhD President & CEO.
FROM CODE TO CURE TM Corporate Overview October 2018 Anat Cohen-Dayag, PhD President & CEO 1 www.cgen.com SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationAddressing challenges of targeting the macrophage checkpoint, CD47. Marie Kosco-Vilbois, PhD CSO
Addressing challenges of targeting the macrophage checkpoint, CD47 Marie Kosco-Vilbois, PhD CSO 1 CD47 is an immune checkpoint Cancer cell Macrophage Activating eat me signal CD47 Inhibitory don t eat
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationUSING THE HUMAN IMMUNE SYSTEM TO CHANGE THE PARADIGM OF CANCER TREATMENT. CORPORATE OVERVIEW March 2016
USING THE HUMAN IMMUNE SYSTEM TO CHANGE THE PARADIGM OF CANCER TREATMENT CORPORATE OVERVIEW March 2016 Immunome Overview A biotechnology company leveraging tumor immunology to develop cancer therapeutics
More informationSECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP. Form: 8-K. Date Filed:
SECURITIES & EXCHANGE COMMISSION EDGAR FILING MYMETICS CORP Form: 8-K Date Filed: 2018-04-23 Corporate Issuer CIK: 927761 Copyright 2018, Issuer Direct Corporation. All Right Reserved. Distribution of
More informationDevelopment of differentiated immuno-oncology therapeutics by using multivalent Nanobodies
Nanobodies Innovative therapeutics Development of differentiated immuno-oncology therapeutics by using multivalent Nanobodies Immune Checkpoint Inhibitors Europe Sandra Li - 17 November 2016 Forward looking
More informationPieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update
March 22, 2016 Pieris Pharmaceuticals Reports Full-Year 2015 Financial Results and Corporate Update Company to Host an Investor Conference Call on Wednesday, March 23, 2016 at 10:00 AM ET BOSTON, MA --
More informationIncyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs
Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs November 1, 2016 $224 million of 2016 third-quarter net product revenues from Jakafi (ruxolitinib), representing 39
More informationCorporate Overview. February Anat Cohen-Dayag, PhD President & CEO.
Corporate Overview February 2019 Anat Cohen-Dayag, PhD President & CEO 1 www.cgen.com SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationALLIGATOR BIOSCIENCE. Eva Dahlén, PhD Senior Director, Business Development
00 ALLIGATOR BIOSCIENCE Eva Dahlén, PhD Senior Director, Business Development 1 Disclaimer FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that provide Alligator s expectations
More informationCreating Innovative Cancer Immunotherapies by Leveraging Underexploited Biological Opportunities April 2018
Creating Innovative Cancer Immunotherapies by Leveraging Underexploited Biological Opportunities April 2018 Forward-Looking Statements / Safe Harbor This presentation contains forward-looking statements
More information(212) Cellectis Media Contact: Philippe Valachs +33(0)
For immediate release: June 18, 2014 Pfizer Media Contact: Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com Cellectis Media Contact: Philippe Valachs +33(0)1 81 69 16 00 media@cellectis.com Pfizer
More informationUS IMMUNO-ONCOLOGY STRATEGY MEETING 2018
CONFIRMED FACILITATORS William Hearl Ramon Mohanlal Robert Iannone President & Chief Executive Officer Immunomic Therapeutics Executive Vice President & Chief Medical Officer BeyondSpring Pharmaceuticals
More informationAntibody therapeutic approaches for cancer
Antibody therapeutic approaches for cancer Date2innovate Utrecht, March 21, 2014 Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect,
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationAravive s Lead Drug Candidate - AVB-S6-500
Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics - Tolerability and proof-of-mechanism for lead
More information35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO
35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationJefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationBioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
November 9, 2018 BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update NEW HAVEN, Conn., Nov. 09, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ( BTI ) (Nasdaq:
More informationAccelerating our priorities Emma Walmsley, Chief Executive Officer
Accelerating our priorities Emma Walmsley, Chief Executive Officer January 2019 1 Information regarding forward-looking statements and non IFRS measures This presentation may contain forward-looking statements.
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationImmuno-Oncology Program
Immuno-Oncology Program 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities
August 9, 2016 ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities Company to Host Conference Call at 4:30 PM ET Today BOSTON, Aug. 09, 2016 (GLOBE NEWSWIRE)
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationNovel Cell-Based Assays to Accelerate Cancer Immunotherapies. Abhi Saharia, Ph. D. Director, Cell-Based Assays
Novel Cell-Based Assays to Accelerate Cancer Immunotherapies Abhi Saharia, Ph. D. Director, Cell-Based Assays 1 ionc drugs Powerful Cancer Treatments Clinical success of Checkpoint mabs from Merck & BMS
More informationNeutralising Assay Methodologies
Neutralising Assay Methodologies March 9 th, 2016 EMA workshop on immunogenicity assessment of biotechnology derived therapeutic proteins Shalini Gupta, PhD Amgen Inc. shalinig@amgen.com 1 Key Points About
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationQ4 and Full Year 2017 Conference Call. February 22, 2018
Q4 and Full Year 2017 Conference Call February 22, 2018 Agenda Welcome McDavid Stilwell VP, Corporate Communications and Investor Relations Q4 2017 and Full Year Review and Recent Highlights Dr. Sandy
More informationDevelop Successful Combination Strategies Validate Novel Pathways Identify Clinically Relevant Biomarkers
2nd Annual Boston Develop Successful Combination Strategies Validate Novel Pathways Identify Clinically Relevant Biomarkers 33 Expert Speakers Including: Roy Baynes SVP, Global Clinical Merck Michael Giordano
More informationDepoVax TM : A novel delivery formulation for cancer immunotherapy and infectious disease vaccines
DepoVax TM : A novel delivery formulation for cancer immunotherapy and infectious disease vaccines May 10, 2017 The DepoVax Platform A patented oil-based formulation NOT an adjuvant Creates powerful vaccines
More informationOX40 MARKET LANDSCAPE
OX40 Agonist OX40 MARKET LANDSCAPE OX40 (a.k.a. CD134) is a costimulatory molecule belonging to the TNF receptor family expressed primarily on activated effector T (T eff) cells and naive regulatory T
More informationNasdaq: MBRX. Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017
Nasdaq: MBRX Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 November 14, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a
More informationAffimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Corporate Presentation September, 2018 Forward-looking statements / safe harbor This
More informationAffimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer
Affimed: Developing First-In-Class Immune Cell Engagers for Harnessing Innate and Adaptive Immunity to Fight Cancer Corporate Presentation October, 2018 Forward-looking statements / safe harbor This presentation
More informationHARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY: A Paradigm Shift in Play
ASX:IMU HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY: A Paradigm Shift in Play Nicholas Ede, PhD Chief Technology Officer Bioshares Biotech Summit July 27 / 2018 NOTICE: FORWARD LOOKING STATEMENTS Imugene
More informationEOS: a Focussed Oncology Company Overview Forum della Ricerca e dell Innovazione Padova, May 16, 2008
Growing and Nurturing Right Ideas EOS: a Focussed Oncology Company Overview Forum della Ricerca e dell Innovazione Padova, May 16, 2008 EOS S.p.A. (Ethical Oncology Science) Via Monte di Pietà 1/A, Milan,
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Michael Severino Vice Chairman and President January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or
More informationADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT
FOR IMMEDIATE RELEASE December 21, 2017 Eisai Co., Ltd. Biogen Inc. ADAPTIVE PHASE II STUDY OF BAN2401 IN EARLY ALZHEIMER S DISEASE CONTINUES TOWARD 18-MONTH ENDPOINT CRITERIA FOR SUCCESS AT 12-MONTH ANALYSIS
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): Modulating immune checkpoint pathways like CTLA-4 and PD-1 for cancer immunotherapy has gained much attention in recent years due to their immense
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationBeyond Machines for Antigen Selection: Using ATLAS to Enable Novel Cancer Immunotherapies. J a n u a r y
Beyond Machines for Antigen Selection: Using ATLAS to Enable Novel Cancer Immunotherapies J a n u a r y 2 0 1 9 Disclaimer This presentation contains forward-looking statements that are within the meaning
More informationArsanis, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTHE FUTURE OF VACCINES
THE FUTURE OF VACCINES NEEDHAM HEALTHCARE CONFERENCE NEW YORK 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors,
More informationGENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Diane Schrick (650) 225-1599 Advocacy Contact: Kristin Reed (650) 467-9831 GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT
More informationINVESTOR PRESENTATION 2018
INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and
More informationDriving the immune system to fight cancer and infectious disease. Jefferies 2015 Healthcare Conference
a June Driving the immune system to fight cancer and infectious disease Jefferies 2015 Healthcare Conference 2015 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements.
More informationMedia Release. Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
Media Release Basel, 12 January 2015 Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology Collaboration leverages both companies strengths
More informationMarch 13, Dear Shareholder:
15245 Shady Grove Road Suite 470 Rockville, MD 20850 301.208.9191 March 13, 2017 Dear Shareholder: We would like to take this time to report on the business activities and accomplishments of RegeneRx in
More informationRecent Trends in Companion Diagnostic Test Development Partnerships
Recent Trends in Companion Diagnostic Test Development Partnerships Andrew S. Thompson, PhD, Director of Therapy and Analysis, GlobalData Medical, London Tyler Fletcher, Global Head, GlobalData Medical,
More informationCATALYST BIOSCIENCES. Corporate Overview. 9 April 2019
1 CATALYST BIOSCIENCES Corporate Overview 9 April 2019 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements,
More information